Endo International plc (NASDAQ:ENDP) Brief Update on Interests

0

Endo International plc (NASDAQ:ENDP – Get Rating) (TSE:ENL) saw strong growth in short-term interest in the month of June. As of June 15, there was short interest totaling 32,790,000 shares, a growth of 31.0% from the May 31 total of 25,040,000 shares. Based on an average daily volume of 14,740,000 shares, the day-to-cover ratio is currently 2.2 days. Approximately 16.3% of the company’s shares are sold short.

A number of hedge funds have recently changed their stock holdings. Carolina Wealth Advisors LLC increased its stake in Endo International by 20.2% during the first quarter. Carolina Wealth Advisors LLC now owns 29,862 shares of the company valued at $69,000 after purchasing an additional 5,028 shares during the period. Sterling Investment Advisors Ltd. increased its stake in Endo International by 36.3% during the first quarter. Sterling Investment Advisors Ltd. now owns 37,515 shares of the company valued at $87,000 after purchasing an additional 10,000 shares during the period. NorthCrest Asset Management LLC bought a new position in Endo International during the first quarter, valued at approximately $28,000. Nisa Investment Advisors LLC increased its stake in Endo International by 500.0% during the fourth quarter. Nisa Investment Advisors LLC now owns 18,000 shares of the company valued at $57,000 after purchasing an additional 15,000 shares during the period. Finally, First Quadrant LLC CA bought a new position in Endo International during the first quarter worth approximately $36,000. 80.39% of the shares are currently held by institutional investors.

NASDAQ:ENDP shares opened at $0.57 on Tuesday. The company has a market capitalization of $134.01 million, a PE ratio of -0.18 and a beta of 1.11. The company’s 50-day simple moving average is $0.83 and its 200-day simple moving average is $2.21. Endo International has a 1-year low of $0.28 and a 1-year high of $7.07.

Endo International (NASDAQ:ENDP – Get Rating) (TSE:ENL) last released its results on Thursday, May 5. The company reported EPS of $0.66 for the quarter, beating analyst consensus estimates of $0.44 by $0.22. The company posted revenue of $652.26 million for the quarter, versus analyst estimates of $637.09 million. Endo International had a negative net margin of 24.82% and a negative return on equity of 72.22%. The company’s quarterly revenue decreased 9.1% from the same quarter last year. During the same period last year, the company posted earnings per share of $0.73. On average, sell-side analysts expect Endo International to post EPS of 0.79 for the current fiscal year.

A number of research companies have weighed in on ENDP recently. BMO Capital Markets cut its price target on Endo International shares from $4.00 to $2.00 in a Monday, May 9 research report. Barclays cut its price target on Endo International shares from $2.00 to $1.00 in a Monday May 9 research report. StockNews.com began covering Endo International shares in a research report on Saturday. They issued a “holding” rating on the stock. Piper Sandler downgraded shares of Endo International from a “neutral” rating to an “underweight” rating and lowered her price target for the stock from $3.00 to $1.00 in a report of research from Friday, May 6. Finally, Citigroup reduced its price target on Endo International shares from $11.00 to $6.00 and set a “buy” rating on the stock in a Wednesday, March 9 research report. Two analysts rated the stock with a sell rating, two assigned a hold rating and one assigned the company a buy rating. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $3.00.

Endo International Company Profile (Get a rating)

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceutical products in the United States and around the world. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren’s disease; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, injectable treatment for moderate to severe cellulite of the buttocks in adult women; PERCOCET to treat moderate to moderately severe pain; TESOPEL an implantable pellet indicated for TRT in pathologies associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch containing lidocaine for pain relief; and products for pain management and urology.

Featured Articles



Get news and reviews for Endo International Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Endo International and related companies with MarketBeat.com’s FREE daily newsletter.

Share.

About Author

Comments are closed.